Sinopharm Group Dirección
Dirección controles de criterios 4/4
El CEO de Sinopharm Group's es Yong Liu , nombrado en Nov 2017, tiene una permanencia de 6.42 años. compensación anual total es CN¥6.28M, compuesta por 33.1% salario y 66.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.002% de las acciones de la empresa, por valor de HK$1.24M. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 5.3 años, respectivamente.
Información clave
Yong Liu
Chief Executive Officer (CEO)
CN¥6.3m
Compensación total
| Porcentaje del salario del CEO | 33.1% |
| Permanencia del CEO | 6.5yrs |
| Participación del CEO | 0.002% |
| Permanencia media de la dirección | 4.4yrs |
| Promedio de permanencia en la Junta Directiva | 5.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22
Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend
Feb 18
Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?
Feb 03Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?
Jan 19At HK$19.00, Is It Time To Put Sinopharm Group Co., Ltd. (HKG:1099) On Your Watch List?
Jan 06What Type Of Shareholders Make Up Sinopharm Group Co., Ltd.'s (HKG:1099) Share Registry?
Dec 25Read This Before Buying Sinopharm Group Co., Ltd. (HKG:1099) Shares
Dec 15We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Dec 04Sinopharm Group's (HKG:1099) Stock Price Has Reduced 43% In The Past Five Years
Nov 25Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | CN¥9b |
| Dec 31 2023 | n/a | n/a | CN¥9b |
| Sep 30 2023 | n/a | n/a | CN¥9b |
| Jun 30 2023 | n/a | n/a | CN¥9b |
| Mar 31 2023 | n/a | n/a | CN¥9b |
| Dec 31 2022 | CN¥6m | CN¥2m | CN¥9b |
| Sep 30 2022 | n/a | n/a | CN¥8b |
| Jun 30 2022 | n/a | n/a | CN¥8b |
| Mar 31 2022 | n/a | n/a | CN¥8b |
| Dec 31 2021 | CN¥7m | CN¥2m | CN¥8b |
| Sep 30 2021 | n/a | n/a | CN¥8b |
| Jun 30 2021 | n/a | n/a | CN¥8b |
| Mar 31 2021 | n/a | n/a | CN¥8b |
| Dec 31 2020 | CN¥7m | CN¥2m | CN¥7b |
| Sep 30 2020 | n/a | n/a | CN¥7b |
| Jun 30 2020 | n/a | n/a | CN¥6b |
| Mar 31 2020 | n/a | n/a | CN¥6b |
| Dec 31 2019 | CN¥7m | CN¥2m | CN¥6b |
| Sep 30 2019 | n/a | n/a | CN¥6b |
| Jun 30 2019 | n/a | n/a | CN¥6b |
| Mar 31 2019 | n/a | n/a | CN¥6b |
| Dec 31 2018 | CN¥8m | CN¥2m | CN¥6b |
| Sep 30 2018 | n/a | n/a | CN¥6b |
| Jun 30 2018 | n/a | n/a | CN¥6b |
| Mar 31 2018 | n/a | n/a | CN¥5b |
| Dec 31 2017 | CN¥6m | CN¥1m | CN¥6b |
Compensación vs. Mercado: La compensación total ($USD866.48K) de Yong está en línea con el promedio de empresas de tamaño similar en el mercado Hong Kong ($USD924.91K).
Compensación vs. Ingresos: La compensación de Yong ha sido consistente con los resultados de la empresa en el último año.
CEO
Yong Liu (54 yo)
6.5yrs
Permanencia
CN¥6,276,000
Compensación
Mr. Yong Liu serves as the Chief Legal Advisor at Sinopharm Group Co. Ltd. and served as its Joint Company Secretary since October 28, 2016 until August 24, 2018. Mr. Liu is Executive Director of Sinopharm...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman of the Board | 5.4yrs | CN¥6.49m | 0.0032% CN¥ 2.0m | |
| President & Executive Director | 6.5yrs | CN¥6.28m | 0.0019% CN¥ 1.2m | |
| Chief Financial Officer | 3.2yrs | sin datos | sin datos | |
| Secretary to the Board | 5.4yrs | sin datos | sin datos |
4.4yrs
Permanencia media
53.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de 1099 se considera experimentado (4.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman of the Board | 5.4yrs | CN¥6.49m | 0.0032% CN¥ 2.0m | |
| President & Executive Director | 6.4yrs | CN¥6.28m | 0.0019% CN¥ 1.2m | |
| Non-Executive Vice Chairman | 14yrs | sin datos | sin datos | |
| Non-Executive Director | 2.9yrs | sin datos | sin datos | |
| Chief Supervisor | 2.9yrs | sin datos | sin datos | |
| Non-Executive Director | 16.8yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 3.7yrs | CN¥350.00k | sin datos | |
| Independent Non-Executive Director | 3.7yrs | CN¥350.00k | sin datos | |
| Non-Executive Director | 6.7yrs | sin datos | sin datos | |
| Non-Executive Director | 5.4yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 5.4yrs | CN¥350.00k | sin datos | |
| Independent Non-Executive Director | 3.7yrs | CN¥350.00k | sin datos |
5.4yrs
Permanencia media
56yo
Promedio de edad
Junta con experiencia: La junta directiva de 1099 se considera experimentada (5.3 años de antigüedad promedio).